Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Journal of Nephrology & Renal DiseasesISSN: 2576-3962
https://sporbahisleri.livejournal.com https://wakelet.com/@SporBahisleri67459 https://theomnibuzz.com/author/sporbahisleri/ https://lessons.drawspace.com/profile/322207/sporbahisleri/workflow https://writeupcafe.com/profile/sporbahisleri/ http://www.pearltrees.com/sporbahisleri https://pharmahub.org/members/26874/blog https://www.zupyak.com/u/Spor-Bahisleri/ https://www.metroflog.co/sporbahisleri https://www.fuzia.com/fz/spor-bahisleri https://tr.pinterest.com/sporbahislerim/ https://my.getjealous.com/sporbahisleri https://sporbahisleri.contently.com https://hubpages.com/@sporbahisleri https://www.tumblr.com/sporbahisleri https://hub.docker.com/u/sporbahislerim https://betsiteleri.blogfree.net https://betsiteleri.amebaownd.com https://sporbahisleri.pixnet.net/blog https://betsiteleri.seesaa.net https://betsiteleri.threadless.com https://betsiteleri.neocities.org https://bahissiteleri.localinfo.jp https://betsiteleri.shopinfo.jp https://teletype.in/@betsiteleri https://ubl.xml.org/users/sporbahisleri https://betsiteleri.educatorpages.com https://betsiteleri.onlc.fr https://sporbahisleri.gumroad.com
Domenico Russo Author
Subjects of specialization
Affiliation
Nephrology
Associate Professor, University of Naples Federico II
Biography
Dr. Domenico Russo associate professor of nephrology at University of Naples Federico, Italy. Dr. Domenico Russo associate professor of nephrology at University of Naples Federico, Italy. Dr. Domenico Russo associate professor of nephrology at University of Naples Federico, Italy
Publications
Conference Proceeding Open Access
Potency and safety of etelcalcetide in patients gaining hemodialysis with secondary hyperparathyroidism: A true case study
Author(s): Domenico Russo
Etelcalcetide is a novel calcimimetic designated for the treatment of secondary hyperparathyroidism (SHPT) in dialysis patients. Etelcalcetide efficacy in SHPT has been determined only in randomized controlled trials. This multicenter study was passed out in “real world” setting that is different from randomized controlled trials (RCTs) to (1) evaluate the effectiveness of etelcalcetide in SHPT, (2) to assess calcium, phosphorus, alkaline phosphatase changes, (3) to register gastrointestinal side effects. Data were collected from twenty-three dialysis units with n = 1190 patients on the charge. From this cohort, n = 168 (14%) patients were on treatment with etelcalcetide, and they were evaluated for statistics. A median weekly dose of etelcalcetide was 15 mg (7.5–45 mg... view more»
Google Scholars / Researchers Sites
